



FREESTYLE LIBRE 3 SYSTEM

Formulary Kit



Medicare and other payor criteria may apply. Abbott provides this information as a courtesy and does not guarantee payment or coverage. Product images are for illustrative purpose only.

The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners.

See Important Safety Information on page 13.

Proprietary and confidential — do not distribute. © 2026 Abbott. ADC-48353 v9.0



April, 2026

Dear Health Plan Administrator,

We are pleased to present Abbott's next-generation system, the FreeStyle Libre 3 system.

The FreeStyle Libre 3 system is a continuous glucose monitoring (CGM) device with real-time alarms* and glucose readings that update automatically every minute. The inclusion of the FreeStyle Libre 3 Plus sensor broadens the indication to people living with diabetes ages 2 and older, and includes features, such as:

- Outstanding 15-day accuracy across multiple measures, with an 8.2% MARD¹
- Our longest data storage—15-day data storage^{†2} makes data gaps a thing of the past
- Easy to use^{‡3}, one-piece sensor application, requiring no in-person training⁴
- The world's smallest, thinnest[§], and most discreet⁴ sensor

This FreeStyle Libre 3 system Formulary Kit contains the following:

- Product information
- Product comparison
- Clinical guidelines
- Clinical highlights
- Digital health tools
- Pricing information
- Prescribing information
- Resources

Please reach out to your Abbott account manager for more information about the FreeStyle Libre 3 system.

Best regards,

Jody Boeddeker

General Manager, Market Access

* Alarm notifications will only be received when alarms settings are enabled and turned on and sensor is within 33 feet unobstructed of the reading device.
† In comparison with other FreeStyle Libre systems sensors. ‡ Study was performed with the outside US version of the FreeStyle Libre 14 day system. Data is applicable to FreeStyle Libre 3 system, as feature sets are similar. § Among patient-applied sensors.

References: **1.** FreeStyle Libre 3 User's Manual. **2.** Based on FreeStyle Libre Systems User Manuals. **3.** Alva S, et al. *Diabetes Ther* (2023): 767-776. <https://doi.org/10.1007/s13300-023-01385-6>. **4.** Data on file, Abbott Diabetes Care.

See Important Safety Information on page 13.

Product Information	Pages 4-5
Product Comparison	Page 6
Digital Health Tools	Page 7
Clinical Guidelines for the Use of CGM: Highlights	Page 8
Clinical Outcomes: Highlights	Page 9
Pricing Information	Page 10
Prescribing Information	Page 11
Resources	Page 12
Important Safety Information	Page 13

Using the FreeStyle Libre 3 Plus sensor helps to build a complete glycemic picture that enables patients, caregivers, and healthcare providers to make informed disease management and treatment decisions.

The FreeStyle Libre 3 Plus sensor is easy to apply and comfortable to wear¹.



FreeStyle Libre 3 Plus sensor


The FreeStyle Libre 3 Plus sensor brings the latest innovative technology to the FreeStyle Libre 3 system, adding the following features:

- Extends the sensor wear up to 15 days²
- Accurate, minute-to-minute glucose data can be combined with compatible automated insulin delivery systems
- Expands the age indication to 2 years and older²



The Libre app*

The Libre app is designed to be used by people living with diabetes. The app enables the user to carry out routine glucose monitoring using a compatible smartphone and the FreeStyle Libre 3 Plus sensor. The Libre app is designed to offer 3 optional alarms[†] (low glucose, high glucose, and signal loss) and 1 mandatory urgent low alarm (set at 55 mg/dL).



FreeStyle Libre 3 reader[‡]

The reader obtains glucose readings via streaming from the sensor and can issue glucose alarms[†]. It is handheld and lightweight, with a backlit color touchscreen. The reader can store approximately 90 days of glucose history and notes entered about activities, such as taking insulin, eating food, or exercising. This information can help patients understand how these activities affect their glucose. The reader also includes a built-in meter for blood glucose testing. To use the built-in meter, patients need the FreeStyle Precision Neo blood glucose test strips, control solution, a lancing device, and lancets. These items are not included in the reader kit and must be obtained separately from their FreeStyle Libre 3 system provider (pharmacy[§] or mail-order supplier).

Medicare and other payor criteria may apply. Abbott provides this information as a courtesy and does not guarantee payment or coverage.

Product images are for illustrative purpose only.

FreeStyle Libre 3 Plus sensors are indicated for use in people with diabetes age 2 and older.

* The FreeStyle Libre systems apps are only compatible with certain mobile devices and operating systems. Please check the Support section of our website for more information about device compatibility before using the apps. Use of the FreeStyle Libre systems apps may require registration with LibreView. † Alarm notifications will only be received when alarms settings are enabled and turned on and sensor is within 33 feet unobstructed of the reading device. ‡ The FreeStyle Libre systems apps and the FreeStyle Libre systems readers have similar but not identical features. Fingersticks are required for treatment decisions when you see the Check Blood Glucose symbol and when your glucose alarms and readings from the system do not match symptoms or expectations. § Participating pharmacies are subject to change without notice. Product availability may vary by retailer or DME.

References: 1. Alva S, et al. *Diabetes Ther* (2023): <https://doi.org/10.1007/s13300-023-01385-6>. 2. FreeStyle Libre 3 User's Manual.

See Important Safety Information on page 13.

Proprietary and confidential — do not distribute. © 2026 Abbott. ADC-48353 v9.0

Alarms

The FreeStyle Libre 3 system provides real-time glucose alarms* with readings streaming every minute. The system is designed to offer 3 optional alarms (low glucose, high glucose, and signal loss) and 1 mandatory urgent low alarm (set at 55 mg/dL).



Optional low glucose alarm:

Notifies when glucose is **BELOW** a set level (60–100 mg/dL)



Optional high glucose alarm:

Notifies when glucose is **ABOVE** a set level (120–400 mg/dL)



Optional signal loss alarm:

Notifies when sensor is **NOT** communicating with smartphone[†] or reader[‡] and that low or high glucose alarms will not be received



The Libre app[†] also has a mandatory **Urgent Low Glucose Alarm** that lets users know when their glucose value is below 55 mg/dL.

Overall Accuracy to YSI

FreeStyle Libre 3 Plus sensor¹

Subject Group	Number of CGM Reference Pairs	Number of Subjects	Percent within $\pm 20\% / \pm 20$ mg/dL	Percent within $\pm 20\% / \pm 20$ mg/dL on Day 1	Percent within $\pm 20\% / \pm 20$ mg/dL in first 12 hours	MARD (%)
Adults	20497	149	93.7	82.9	79.2	8.2
Children (age 6–17)	7025	124	93.5	89.8	90.5	8.2
Children (age 2–5) [§]	135	10	86.7	78.9	88.9	9.7

Medicare and other payor criteria may apply. Abbott provides this information as a courtesy and does not guarantee payment or coverage.

Product images are for illustrative purpose only.

* Alarm notifications will only be received when alarms settings are enabled and turned on and sensor is within 33 feet unobstructed of the reading device.

[†] The FreeStyle Libre systems apps are only compatible with certain mobile devices and operating systems. Please check the Support section of our website for more information about device compatibility before using the apps. Use of the FreeStyle Libre systems apps may require registration with LibreView. [‡] The FreeStyle Libre systems apps and the FreeStyle Libre systems readers have similar but not identical features. Fingersticks are required for treatment decisions when you see the Check Blood Glucose symbol and when your glucose alarms and readings from the system do not match symptoms or expectations. [§] No YSI measurements were obtained for children ages 2–5; results displayed are from CGM-SMBG matched paired measurements obtained during clinic visits from 10 of the 12 subjects. Two of the 12 subjects did not have CGM-SMBG matched paired measurements obtained from clinic visits.

Reference: 1. FreeStyle Libre 3 User's Manual.

See Important Safety Information on page 13.

Proprietary and confidential — do not distribute. © 2026 Abbott. ADC-48353 v9.0

**FreeStyle Libre 2 system with
FreeStyle Libre 2 Plus sensor¹**

**FreeStyle Libre 3 system with
FreeStyle Libre 3 Plus sensor²**


Glucose data transfer to reader/smartphone	Real-time glucose readings and real-time alarms*	
Glucose viewing	Scan or stream [to app [†] , reader [‡] , automated insulin delivery device (AID)]	Stream [to app, reader, or AID]
Sensor wear	15-day	
Indication	The FreeStyle Libre systems are indicated for all people with diabetes, including those with type 1 diabetes and type 2 diabetes.	
Configuration	Sensor with app or reader  	
Applicator	2-piece	1-piece
Age	2 and older	
Sensor size	1.18 x 0.2 in 	0.83 x 0.11 in 
AID compatibility	Yes	

Medicare and other payor criteria may apply. Abbott provides this information as a courtesy and does not guarantee payment or coverage.

Product images are for illustrative purpose only.


FreeStyle Libre 2 Plus and FreeStyle Libre 3 Plus sensors are indicated for use in people with diabetes age 2 and older.

* Alarm notifications will only be received when alarms settings are enabled and turned on and sensor is within 20 feet (FreeStyle Libre 2) or 33 feet (FreeStyle Libre 3) unobstructed of the reading device. [†] The FreeStyle Libre systems apps are only compatible with certain mobile devices and operating systems. Please check the Support section of our website for more information about device compatibility before using the apps. Use of the FreeStyle Libre systems apps may require registration with LibreView. [‡] The FreeStyle Libre systems apps and the FreeStyle Libre systems readers have similar but not identical features. Fingersticks are required for treatment decisions when you see the Check Blood Glucose symbol and when your glucose alarms and readings from the system do not match symptoms or expectations.

References: 1. FreeStyle Libre 2 User's Manual. 2. FreeStyle Libre 3 User's Manual.

See Important Safety Information on page 13.

Proprietary and confidential — do not distribute. © 2026 Abbott. ADC-48353 v9.0



The Libre app* — *for the patient*

The Libre app provides real-time glucose readings streamed every minute directly to your member's smartphone* so they can act faster and make timely diabetes treatment decisions.

With helpful reports, easy-to-read charts, and the ability to privately share† user's glucose readings with up to 20 individuals from their care team, the Libre app helps users manage their diabetes daily.

The Libre Assist‡ feature within the app aligns with the ADA's latest medical nutrition guidelines. It promotes eating whole foods, following practical eating habits, and adhering to sustainable eating patterns.

The Libre app supports both English and Spanish language users.



LibreLinkUp app§ — *for the caregivers*

The LibreLinkUp app is designed to be used by family, friends, and other caregivers of patients using the Libre app. The LibreLinkUp app allows users to follow up to 20 different connections. LibreLinkUp users receive real-time glucose information (including a 12-hour graph) and can customize their own glucose alarms¶¶.



LibreView desktop application# — *for the healthcare professional and the patient*

LibreView is a secure, cloud-based data management system. It is HIPAA compliant and allows data to be accessed at any time. Streamed glucose data is compiled into easy-to-interpret¹ reports, glucose patterns, and trends. LibreView is intended for use by both patients and healthcare professionals to assist people living with diabetes.

Medicare and other payor criteria may apply. Abbott provides this information as a courtesy and does not guarantee payment or coverage.

Product images are for illustrative purpose only.

* The FreeStyle Libre systems apps are only compatible with certain mobile devices and operating systems. Please check the Support section of our website for more information about device compatibility before using the apps. Use of the FreeStyle Libre systems apps may require registration with LibreView.

† The user's device must have internet connectivity for glucose data to automatically upload to LibreView and to transfer to connected LibreLinkUp app users. ‡ Libre Assist is a feature within Libre app that uses generative artificial intelligence to provide information on how foods could impact your glucose levels. Generative artificial intelligence may not always be accurate, and it should not be used to make treatment decisions. § Check <https://www.librelinkup.com/> for information about mobile device and operating system compatibility. LibreLinkUp is not intended to be used for dosing decisions or to replace self-monitoring practices as advised by a physician, and requires registration with LibreView. ¶ Alarm notifications will only be received when alarms settings are enabled and turned on and sensor is within 33 feet unobstructed of the reading device. ¶¶ Glucose alarms will transfer to the LibreLinkUp app users when users are connected and alarms are enabled on the Libre app. # The LibreView data management software is intended for use by both patients and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis and evaluation of historical glucose meter data to support effective diabetes management. The LibreView software is not intended to provide treatment decisions or to be used as a substitute for professional healthcare advice.

Reference: 1. Unger, J. *Postgrad Med* (2020): <https://doi.org/10.1080/00325481.2020.1744393>

See Important Safety Information on page 13.

Proprietary and confidential — do not distribute. © 2026 Abbott. ADC-48353 v9.0

Clinical Guidelines for the Use of CGM: Highlights

Respected clinical organizations, including the ADA and AACE, have published guidelines for the use of continuous glucose monitoring (CGM) in the management of diabetes^{1,2}.

American Diabetes Association (ADA) American Diabetes Association®

2026 ADA Standards of Care Recommendations on CGM Use¹:

The ADA published diabetes treatment guidelines as part of the 2026 Standards of Care in Diabetes, making the following recommendations for CGM use¹ pertaining to all types of diabetes, brand choices, and access:

- Now recommended at diabetes onset and anytime thereafter for children, adolescents, and adults with diabetes who are on insulin therapy, on noninsulin therapies that can cause hypoglycemia, and on any diabetes treatment where CGM helps in management
- Use of CGM for older adults with type 1 diabetes or type 2 diabetes on insulin to improve glycemic outcomes, reduce hypoglycemia, and reduce treatment burden
- CGM can help achieve glycemic goals and A1c goal in type 1 diabetes and pregnancy and may be beneficial for other types of diabetes in pregnancy
- The choice of device should be made based on the individual's circumstances, preferences, and needs
- People with diabetes should have uninterrupted access to their supplies to minimize gaps in CGM

American Association of Clinical Endocrinology (AACE) AACE®

2023 AACE Clinical Practice Guidelines Recommendations on CGM Use²:

The AACE published recommendations in 2023 regarding the use of CGM systems in the management of people with diabetes. The following recommendations were highlighted with respect to continuous glucose monitoring:

- For all patients to reach glycemia goals safely
- For newly diagnosed T2DM patients and those at low risk for hypoglycemia
- For the use of CGM metrics, which can be used as a surrogate to HbA1c
- For the education of persons with T2DM (eg, effects on behaviors including diet and exercise)
- For alarms or alerts in persons with hypoglycemia who would benefit from these warnings
- For aiding clinicians in investigating avenues to improve glycemic control with medical therapies

References: 1. American Diabetes Association Professional Practice Committee for Diabetes; 7. Diabetes Technology: Standards of Care in Diabetes—2026. *Diabetes Care* (2026); 49 (Supplement_1): S150–S165. <https://doi.org/10.2337/dc26-S007> Accessed January 2026. 2. Samson SL, et al. *Endocr Pract* (2023). <https://doi.org/10.1016/j.eprac.2023.02.001>

See Important Safety Information on page 13.

Proprietary and confidential — do not distribute. © 2026 Abbott. ADC-48353 v9.0

8 of 14

Use of FreeStyle Libre personal CGMs is associated with:

Reduced HbA1c across multiple groups of patients* ¹⁻⁹	Increased Time in Range (TIR)* ^{2,3,10,11}	Reduced number of hypoglycemic events* ¹¹⁻¹³	Reduced resource utilization* ^{5,9,14}
↓ 0.42%-0.59% HbA1c reduction observed among patients with T1D/T2D in a meta-analysis*¹ ↓ 0.4-0.5% HbA1c reduction among children and teenagers (4-17 years) with T1D*^{2,3} ↓ 0.4% HbA1c reduction among patients with T1D*⁴ ↓ 0.9-1.6% reduction in HbA1c among people with T2D*⁵⁻⁸ ↓ 2.4% reduction in HbA1c when used in combination with a GLP-1 RA among patients with T2D*⁹	↑ 1-2.17 hrs/day increased TIR observed among patients with T1D*^{2,3,10} ↑ 2.36 hrs/day increased TIR observed among patients with T2D*¹¹	↓ 26% reduction in number of hypoglycemic events among patients with T1D*¹¹ ↓ 28% reduction in number of hypoglycemic events among patients with T2D on intensive insulin regimens*¹² ↓ 44% fewer severe hypoglycemia admissions among patients with T2D*¹³	↓ 83% reduction in number of diabetes-related hospital admissions among patients with T1D or T2D*¹⁴ ↓ 37% reduction in acute diabetes event rates among patients with T2D on basal insulin*⁵ ↓ 25% reduction in acute diabetes event rates among patients with T2D on non-insulin therapies*⁵ ↓ 75% fewer DKA-related hospital admissions among patients with T2D*⁹

* Study was performed with the outside US version of the FreeStyle Libre 14 day system. Data is applicable to FreeStyle Libre 3 system, as feature sets are similar as FreeStyle Libre 14 day system, excluding alarms. † A meta-analysis of 75 real-world observational studies on the impact of flash continuous glucose monitoring on glycemic control as measured by HbA1c. ‡ Acute diabetes events include hospitalizations or outpatient emergency room visits associated with hyper- or hypoglycemic events.

References: 1. Evans, M. *Diabetes Ther* (2022): <https://doi.org/10.1007/s13300-022-01253-9> 2. Campbell, F. *Pediatr Diabetes* (2018): <https://doi.org/10.1111/peidi.12735> 3. Leelarathna L, et al. *N Engl J Med* (2022): <https://doi.org/10.1056/nejmoa2205650> 4. Tyndall, V. *Diabetologia* (2019): <https://doi.org/10.1007/s00125-019-4894-1> 5. Miller M, et al. *Am J Manag Care* (2021): <https://doi.org/10.37765/ajmc.2021.88780> 6. Wright E, et al. *Diabetes Spectr* (2021): <https://doi.org/10.2337/ds20-0069> 7. Miller R, et al. *Diabetes* (2020): <https://doi.org/10.2337/db20-84-LB> 8. Aronson R, et al. *Diabetes Obes Metab*. (2022): <https://doi.org/10.1111/dom.14949> 9. Wright E, et al. Initiating GLP-1 therapy in combination with FreeStyle Libre provides greater benefit compared to GLP-1 therapy alone. Abstract presented at: ATTD 2024, The International Conference on Advanced Technologies & Treatments for Diabetes, March 6-9, 2024; Florence, Italy, and online. 10. Bolinder, J. *Lancet* (2016): [https://doi.org/10.1016/s0140-6736\(16\)31535-5](https://doi.org/10.1016/s0140-6736(16)31535-5) 11. Wada E, et al. *BMJ Open Diabetes Res Care* (2020): <http://dx.doi.org/10.1136/bmjdr-2019-001115> 12. Haak, T. *Diabetes Ther* (2017): <https://doi.org/10.1007/s13300-016-0223-6> 13. Guerci B, et al. *Diabetes Technol Ther* (2022): <https://doi.org/10.1089/dia.2022.0271> 14. Fokkert, M. *BMJ Open Diabetes Res Care* (2019): <https://doi.org/10.1136/bmjdr-2019-000809>

See Important Safety Information on page 13.

Proprietary and confidential — do not distribute. © 2026 Abbott. ADC-48353 v9.0

FreeStyle Libre 3 system



	FreeStyle Libre 3 Plus Sensor ¹	FreeStyle Libre 3 Reader ¹
SKU #	78768-01	72079-01
Quantity	1 sensor	1 reader
Unit Price	\$81.94 ea	\$70.00
NRC	57599-0844-00	57599-0820-00
UPC	357599844011	35799820015
Unit Pkg. Weight	0.13 lb	0.865 lb
Storage Temperature	36°F to 82°F (2.22°C to 27.78°C)	-4°F to 140°F (-20°C to 60°C)
Storage Humidity	10% to 90%	10% to 90%
Contains Battery	Yes	Yes

Medicare and other payor criteria may apply. Abbott provides this information as a courtesy and does not guarantee payment or coverage.

Product images are for illustrative purpose only.

Reference: 1. FreeStyle Libre 3 User's Manual.

See Important Safety Information on page 13.

Proprietary and confidential — do not distribute. © 2026 Abbott. ADC-48353 v9.0

Pharmacy

Commercially insured / cash-pay patients

FreeStyle Libre 3 system Rx includes:

- The Libre app*
- FreeStyle Libre 3 Plus sensor
 - Quantity: 2 sensors/month NRC # 57599-0844-00
 - Sensor refills: PRN or 12 refills annually

Durable Medical Equipment (DME)

Medicare-eligible patients

1. **Determine if patient's coverage is Medicare Fee-for-Service or Medicare Advantage**
 - Medicare Fee-for-Service: Refer to CMS Continuous Glucose Monitors coverage criteria and documentation requirements to confirm coverage^{††}
 - Medicare Advantage: Contact the patient's insurance for eligibility criteria
2. FreeStyle Libre DME Supplier Grid provides options to select DME[§]: <https://www.freestyleprovider.abbott/us-en/dme.html>
3. Medicare Detailed Written Order form to be completed with the patient's information^{†‡||}
 - Medicare Detailed Written Order form can be found at: <http://www.freestylefoundations.abbott>
4. Patient to receive a call from the DME supplier

How to get the Libre app*

Once your member receives their prescription for the FreeStyle Libre 3 system, they can download the app* to their compatible smartphone at no cost.



Medicare and other payor criteria may apply. Abbott provides this information as a courtesy and does not guarantee payment or coverage.

* The FreeStyle Libre systems apps are only compatible with certain mobile devices and operating systems. Please check the Support section of our website for more information about device compatibility before using the apps. Use of the FreeStyle Libre systems apps may require registration with LibreView. † See Local Coverage Determination: Glucose Monitors (L33822), July 2021. <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33822>. ‡ Patients must meet Medicare eligibility coverage criteria. § DMEs are subject to change without notice. || See Local Coverage Article: Glucose Monitors (A52564). <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=52464>

See Important Safety Information on page 13.

Proprietary and confidential — do not distribute. © 2026 Abbott. ADC-48353 v9.0

11 of 14

Sign up to learn more: Payer.FreeStyle.Abbott

- Support for Payers
- Latest Clinical Evidence
- Connect with an Account Manager

Website for providers: FreeStyleProvider.Abbott

- Support for Providers
- How to Prescribe
- Practice Resources

Website for members: FreeStyle.Abbott

- Support for Members
 - Patient Stories
 - Getting Started and MyFreeStyle Program
-



FREESTYLE LIBRE 3 SYSTEM
Important Safety
Information

Product for prescription only, for Important Safety Information please visit
[FreeStyleLibre.us](https://www.FreestyleLibre.us).

The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott.
Other trademarks are the property of their respective owners.



Medicare and other payor criteria may apply. Abbott provides this information as a courtesy and does not guarantee payment or coverage. Product images are for illustrative purpose only.

See Important Safety Information on page 13.

Proprietary and confidential — do not distribute. © 2026 Abbott. ADC-48353 v9.0